Drug Type Monoclonal antibody, Enzyme |
Synonyms Tecentriq Hybreza |
Target |
Mechanism Hyaluronic acid modulators, PDL1 inhibitors(Programmed death-ligand 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (12 Sep 2024), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Alveolar Soft Part Sarcoma | US | 12 Sep 2024 | |
BRAF V600 mutation-positive Melanoma | US | 12 Sep 2024 | |
ES-SCLC | US | 12 Sep 2024 | |
Hepatocellular Carcinoma | US | 12 Sep 2024 | |
Liver Cancer | US | 12 Sep 2024 | |
Lung Cancer | US | 12 Sep 2024 | |
metastatic non-small cell lung cancer | US | 12 Sep 2024 | |
Non-Small Cell Lung Cancer | US | 12 Sep 2024 | |
Non-squamous non-small cell lung cancer | US | 12 Sep 2024 | |
PD-L1 positive Non-Small Cell Lung Cancer | US | 12 Sep 2024 | |
Skin Neoplasms | US | 12 Sep 2024 | |
Small Cell Lung Cancer | US | 12 Sep 2024 | |
Soft Tissue Neoplasms | US | 12 Sep 2024 |